INTRODUCTION AND OBJECTIVES:
To investigate the hemostatic usefulness of oxidized regenerated cellulose patch (ORCP) used immediately after transrectal ultrasound (TRUS)-guided prostate biopsy and assess anxiety and depression in patients undergoing prostate biopsy.
METHODS: 100 patients underwent TRUS-guided prostate biopsy between August 2016 and May 2017 recruited into the retrospective group. In the prospective group, 100 patients received prostate biopsy between June 2017 and March 2018. Systematic 12-core prostate biopsy was performed in all patients. The prospective group received ORCP on biopsy tracts immediately after prostate biopsy, while the retrospective group underwent TRUS-guided prostate biopsy alone. The incidence rate and duration of hematuria, hematospermia, and rectal bleeding were compared between the two groups. Anxiety and depression were assessed with the Hospital Anxiety and Depression Scale (HADS) before and after prostate biopsy in the prospective group.
RESULTS: The incidence rates of hematuria and hematospermia were not significantly different between the two groups (65 vs. 67%, p[0.881; 18 vs. 20%, p[0.718, respectively , for prospective vs. retrospective group). The rectal bleeding incidence was significantly lower in the prospective group as compared to the retrospective group (27 vs. 43%, p[0.018). However, there were no significant differences in the median duration of hematuria, hematospermia, or rectal bleeding between the two groups (2, 5, and 2 days vs. 2, 7, and 1 days, p > 0.05, respectively, for prospective vs. retrospective group). ORCP was significantly protective against the occurrence of rectal bleeding after prostate biopsy in multivariable analysis (p[0.038, odds ratio 0.52). Level of anxiety in the prospective group before versus after prostate biopsy was statistically significant (5 vs. 4, p[0.011), but level of depression was not.
CONCLUSIONS: ORCP on biopsy tract used immediately after TRUS-guided prostate biopsy is an effective method to decrease rectal bleeding. ORCP insertion could alleviate anxiety in patients who received prostate biopsy. RESULTS: The average cost of the 234,819 biopsies reviewed was $2,020, and $920 (46%) of biopsy cost occurred in the 30 days following each biopsy. Biopsies performed in the office setting comprised 66% of total biopsies and were least costly, with an average cost of $1,750. Biopsies performed in ambulatory surgical centers ($2,260) and outpatient hospital settings ($2,730) were more costly than office biopsy (both p<0.001) with most of the additional costs rendered on the day of the biopsy. Biopsies performed within the office setting were associated with fewer complications (10%) compared to the outpatient hospital (19%) or ambulatory surgical center settings (12%; both p<0.001). An uncomplicated biopsy episode averaged across all biopsy settings cost an average of $1,740. This cost increased to $4,060 when at least one complication occurred (Difference þ$2,320; p<0.001) and most of these added costs were seen in the 30 days following a biopsy. The largest charges incurred were related to inpatient hospitalizations ($15,470 versus $1,630 when there was no hospitalization, p<0.001) but was rare constituting only 2.8% of biopsies.
CONCLUSIONS: Nearly half of costs during prostate biopsy episodes occur in the days following a biopsy and are largely related to biopsy complications. These data should be used as benchmarks to incentivize interventions to reduce complications and subsequent admissions following biopsies.
